Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | DRD4 | P21917 | 4/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752776 | 1.00 | DRD2 (0.53) | DRD2DRD4DRD3SLC6A2CHRM2 | |
| SCHEMBL19838609 | 0.89 | CHRM2 (0.51) | DRD2DRD4DRD3SLC6A2CHRM2 | |
| SCHEMBL19839767 | 0.89 | CHRM2 (0.51) | DRD2DRD4DRD3SLC6A2CHRM2 | |
| SCHEMBL6618877 | 0.86 | DRD4 (0.54) | DRD4DRD3SLC6A2CHRM2CHRM4 | |
| SCHEMBL12386018 | 0.83 | CHRM2 (0.49) | DRD4CHRM2CHRM4CHRM5L3MBTL1 | |
| SCHEMBL16422747 | 0.77 | GAA (0.51) | DRD2DRD4DRD3GAAL3MBTL1 | |
| SCHEMBL20483452 | 0.76 | CHRM2 (0.64) | DRD2DRD4DRD3SLC6A2CHRM2 | |
| SCHEMBL6193982 | 0.75 | SIGMAR1 (0.52) | CHRM4OPRM1OPRD1OPRK1HTR2C | |
| SCHEMBL11773404 | 0.74 | CHRM2 (0.53) | DRD2DRD4DRD3SLC6A2CHRM2 | |
| SCHEMBL6217467 | 0.74 | SIGMAR1 (0.47) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1178047-B1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | claimed |
| US-6531468-B2 | Inhibiting serotonin reuptake in the central nervous system of a mammal | PFIZER INC | 2003-03-11 | — | — | US | claimed |
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER INC. | 2002-06-06 | — | — | US | claimed |
| EP-1178047-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| EP-2870140-B1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LTD (IN) | 2016-07-27 | — | — | EP | disclosed |
| EP-2870140-B1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LTD (IN) | 2016-07-27 | — | — | EP | disclosed |
| US-9359367-B2 | Tetrahydroquinazolinone derivatives as PARP inhibitors | LUPIN LIMITED (IN) | 2016-06-07 | — | — | US | disclosed |
| US-9359367-B2 | Tetrahydroquinazolinone derivatives as PARP inhibitors | LUPIN LIMITED (IN) | 2016-06-07 | — | — | US | disclosed |
| US-9359367-B2 | Tetrahydroquinazolinone derivatives as PARP inhibitors | LUPIN LIMITED (IN) | 2016-06-07 | — | — | US | disclosed |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | LUPIN LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | LUPIN LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | LUPIN LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| EP-1178048-B1 | Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5HT2a antagonists | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1178047-B1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6552015-B2 | Inhibition of serotonin reuptake; especially 2-(azabicycloalkyl)alkylenyl)isoquinolin-3-one compounds | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| US-6531468-B2 | Inhibiting serotonin reuptake in the central nervous system of a mammal | PFIZER INC | 2003-03-11 | — | — | US | disclosed |
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
| US-20020052355-A1 | Azabicycloalkane derivatives and therapeutic uses thereof | PFIZER PRODUCTS INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1178048-A1 | Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5HT2a antagonists | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1178047-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | CNR1, CBR1, CLIC1 | DRD2 1075/4885DRD4 1043/4885DRD3 894/4885 |
| US-20020052355-A1 | Azabicycloalkane derivatives and therapeutic uses thereof | HTR5A, HTR1A, HTR2A | DRD2 230/4885DRD4 385/4885DRD3 348/4885 |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | PARP1, PARP11, PARP3 | DRD2 524/4885DRD4 744/4885DRD3 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.